Eledon Pharmaceuticals Inc (ELDN)
2.30
-0.08
(-3.36%)
USD |
NASDAQ |
May 10, 16:00
2.30
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 57.07M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.45% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.6841 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.80% |
Profile
| Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
| URL | https://www.eledon.com |
| Investor Relations URL | http://investors.tokaipharma.com/phoenix.zhtml?c=252857&p=irol-irhome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | May. 10, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. |
| URL | https://www.eledon.com |
| Investor Relations URL | http://investors.tokaipharma.com/phoenix.zhtml?c=252857&p=irol-irhome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | May. 10, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |